"The U.S. Food and Drug Administration today approved the first generic versions of Cymbalta (duloxetine delayed-release capsules), a prescription medicine used to treat depression and other conditions.
Aurobindo Pharma Ltd., Dr. Reddy's La"...
Major Depressive Disorder
APLENZIN® (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM).
The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies].
Seasonal Affective Disorder
APLENZIN is indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD).
The efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in adult outpatients with a history of MDD with an autumn-winter seasonal pattern as defined in the DSM [see Clinical Studies].
DOSAGE AND ADMINISTRATION
APLENZIN should be swallowed whole and not crushed, divided, or chewed. APLENZIN should be administered in the morning and may be taken with or without regard to meals.
Equivalent Daily Doses Of APLENZIN (Bupropion hydrobromide) And Bupropion Hydrochloride
See Table 1 for equivalent daily doses of APLENZIN (bupropion hydrobromide) and bupropion hydrochloride.
Table 1: Equivalent Daily Doses of APLENZIN (Bupropion
hydrobromide) and Bupropion hydrochloride
|APLENZIN (bupropion hydrobromide)||Bupropion hydrochloride|
|522 mg||450 mg|
|348 mg||300 mg|
|174 mg||150 mg|
Dosage For Major Depressive Disorder (MDD)
The recommended starting dose for MDD is 174 mg once daily in the morning. After 4 days of dosing, the dose may be increased to the target dose of 348 mg once daily in the morning.
It is generally agreed that acute episodes of depression require several months or longer of antidepressant treatment beyond the response in the acute episode. It is unknown whether the APLENZIN dose needed for maintenance treatment is identical to the dose that provided an initial response. Periodically reassess the need for maintenance treatment and the appropriate dose for such treatment.
Dosage For Seasonal Affective Disorder (SAD)
The recommended starting dose for SAD is 174 mg once daily. After 7 days of dosing, the dose may be increased to the target dose of 348 mg once daily in the morning. Doses above 300 mg of bupropion HCl extended-release (equivalent to APLENZIN 348 mg) were not assessed in the SAD trials.
For the prevention of seasonal MDD episodes associated with SAD, initiate APLENZIN in the autumn, prior to the onset of depressive symptoms. Continue treatment through the winter season. Taper and discontinue APLENZIN in early spring. For patients treated with 348 mg per day, decrease the dose to 150 mg once daily before discontinuing APLENZIN. Individualize the timing of initiation and duration of treatment should be individualized, based on the patient's historical pattern of seasonal MDD episodes.
To Discontinue APLENZIN, Taper The Dose
When discontinuing treatment in patients treated with APLENZIN 348 mg once daily, decrease the dose to 174 mg once daily prior to discontinuation.
Dosage Adjustment For Patients With Impaired Hepatic Function
Dosage Forms And Strengths
APLENZIN Extended-Release Tablets, 174 mg of bupropion hydrobromide, are white to off-white, round tablets printed with “BR” over “174”.
APLENZIN Extended-Release Tablets, 348 mg of bupropion hydrobromide, are white to off-white, round tablets printed with “BR” over “348”.
APLENZIN Extended-Release Tablets, 522 mg of bupropion hydrobromide, are white to off-white, round tablets printed with “BR” over “522”.
Storage And Handling
APLENZIN® Extended-Release Tablets, 174 mg of bupropion hydrobromide, are white to offwhite, round tablets printed with “BR” over “174” in bottles of 30 tablets (NDC 0024-5810-30).
APLENZIN® Extended-Release Tablets, 348 mg of bupropion hydrobromide, are white to offwhite, round tablets printed with “BR” over “348” in bottles of 30 tablets (NDC 0024-5811-30).
APLENZIN® Extended-Release Tablets, 522 mg of bupropion hydrobromide, are white to offwhite, round tablets printed with “BR” over “522” in bottles of 30 tablets (NDC 0024-5812-30).
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
Manufactured by: Valeant Pharmaceuticals International, Inc. Steinbach, MB, Canada R5G 1Z7. Manufactured for: sanofi-aventis U.S. LLC, Bridgewater, NJ 08807. TBD Rev. 2014
Last reviewed on RxList: 7/24/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Aplenzin Information
Aplenzin - User Reviews
Aplenzin User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get tips on therapy and treatment.